U-2 OS

Osteosarcome (originally called 2T) derived from a moderately differentiated sarcoma of the tibia of a 15 year old human female (Ponten and Saksela (1967) Int. J. Cancer 2: 434-447).

Cell Type:
Bone
Tissue Origin:
bone
Species:
human
Research Area:
Cancer Research/Cell Biology
Cell Characteristics:
Adherent

Recommended Media

McCoy's 5A Medium was developed in 1956 to be formulated for the nutritional requirements of Walker 256 carcinoma. Its unique components include asparagine, 3X normal glucose, amino acids (all Lisomers) and increased folic acid. It is a general purpose medium for primary and established cell lines.

12-168 With L-glutamine and 25 mM HEPES 
12-688 With L-glutamine

Storage = 2ºC to 8ºC

UltraCULTURE™ Medium is a complete all purpose serum-free medium which supports the growth of a wide variety of both non-adherent and adherent cell lines.
The product is ready-to-use with the simple addition of 5.0 ml of L-glutamine solution (Cat. No. 17-605) per 500 ml.

The medium consists of a DMEM:F-12 base which is supplemented with recombinant human insulin, bovine transferrin and a purified mixture of bovine serum proteins including albumin. The total protein concentration of UltraCULTURE™ Medium is approximately 3 mg/ml. UltraCULTURE™ Medium does not contain L-glutamine.

UltraCULTURE™ Medium may be supplemented with Cryoprotective Medium (Cat. No. 12-132) to cryopreserve cells in a serum-free environment.

Storage = 2ºC to 8ºC

PC-1™ is a low-protein, serum-free medium intended for the culture of primary cells and anchorage-dependent cell lines. PC-1 is formulated in a specially modified DMEM/F12 base and contains a complete HEPES buffering system with known amounts of insulin, transferrin, fatty acids, and proprietary proteins assembled under strict quality control procedures. PC-1™ is intended for a variety of research and industrial applications and is formulated using defined components for optimal cell growth, while maintaining the lowest possible protein content.
PC-1™ does not contain L-glutamine.

PC-1™ Liquid Base Medium is to be stored at 2°C-8°C.
The Supplement should be stored at -20°C.
When these two components are combined, the resulting PC-1™ Complete Medium is stable for 45 days at 2°C-8°C.

Once thawed, the appropriate volume of one vial of PC-1™ Supplement must be combined with the companion volume of PC-1™ Liquid Base Medium. Partial reconstitution or repeated freezing and thawing of the PC-1™ Supplement is not advised.

ProCHO™ Protein-free CHO Media were developed specifically to facilitate the production and downstream processing of recombinant proteins expressed in CHO cells. These protein-free formulations support high-density cultures without the need for animal derived components.
Very low levels of recombinant insulin facilitate both downstream purification and regulatory compliance.

The following media systems are available:
- ProCHO™ 4 Medium – For concurrent transition of adherent CHO cells to serum-free and suspension culture; supports faster doubling times
- ProCHO™ 5 Medium – For CHO cells already growing in suspension; supports increased protein production
- ProCHO™ AT Medium – For adherent culture of CHO cells

Storage = 2°C to 8°C

12-029Q - ProCHO™ 4 with phenol red and 0.1% Pluronic® F-68; but without L-glutamine, hypoxanthine, or thymidine.
04-919Q - ProCHO™ 4 with 0.1% Pluronic® F-68; and without phenol red, L-glutamine, hypoxanthine, or thymidine.

12-766Q - ProCHO™ 5  with 0.1% Pluronic® F-68; and without L-glutamine, phenol red, hypoxanthine, or thymidine.
BE15-766 - ProCHO™ 5 powder without phenol red

BE02-016 - ProCHO™-AT contains L-glutamine and does not contain hypoxanthine or thymidine.

UltraMDCK Serum-free Renal Cell Medium is designed to support the growth of MADIN-DARBY Canine Kidney (MDCK) cells at low and high plating densities.
The medium contains only two proteins: recombinant human insulin and bovine transferrin, yielding a very low protein formulation.

Storage = 2ºC to 8ºC

HL-1™ Serum-free Medium Supplement (100X) is a medium additive that can be used to replace serum or significantly reduce its concentration in a variety of basal media.
It contains less than 30 µg protein/ml when diluted 1:100 in medium and it does not contain bovine serum albumin.

Storage = 15°C to 30°C

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
SE CM-104 2e5 99% 91-99% Plasmid (general) 0.4 µg 20 µl 4D X-Unit
SE CM-104 2e6 99% 85-87% Plasmid (general) 2 µg 100 µl 4D X-Unit
V X-001 1e6 97-99% 80-96% Plasmid (general) 2 µg 100 µl I/II/2b

Citations (16)

Categories:
Primary Cells and Media, Transfection, Cell Lines and Primary Cancer Cells 
Authors:
Anzalone AV1,2,3, Randolph PB1,2,3, Davis JR1,2,3, Sousa AA1,2,3, Koblan LW1,2,3, Levy JM1,2,3, Chen PJ1,2,3, Wilson C1,2,3, Newby GA1,2,3, Raguram A1,2,3, Liu DR4,5,6. 
In:
Nature (2019) 10: 1038 
Categories:
Primary Cells and Media, Serum-free and Speciality Media, Transfection 
Authors:
Pavel-Dinu M, Wiebking V, Dejene BT, Srifa W, Mantri S, Nicolas CE, Lee C, Bao G, Kildebeck EJ, Punjya N, Sindhu C, Inlay MA, Saxena N, DeRavin SS, Malech H, Roncarolo MG, Weinberg KI, Porteus MH 
In:
Nat Commun. (2019) 10 (1): 1634 
Categories:
Transfection 
Authors:
Agudelo D, Duringer A, Bozoyan L, Huard CC, Carter S, Loehr J, Synodinou D, Drouin M, Salsman J, Dellaire G, Laganière J, Doyon Y. 
In:
Nat Methods (2017) 14(6): 615-620 
Categories:
Transfection 
Authors:
Bothmer A, Phadke T, Barrera LA, Margulies CM, Lee CS, Buquicchio F, Moss S, Abdulkerim HS, Selleck W, Jayaram H, Myer VE, Cotta-Ramusino C. 
In:
Nat Commun. (2017) 8: 13905 
Categories:
Transfection 
Authors:
Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK 
In:
Nature (2016) 529 (7587): 490-5 
Categories:
Transfection 
Authors:
Shengdar Q. Tsai, Nicolas Wyvekens, Cyd Khayter, Jennifer A. Foden, Vishal Thapar, Deepak Reyon, Mathew J. Goodwin, Martin J. Aryee, J. Keith Joung 
In:
Nat Biotechnol (2014) 32(6): 569-76 
Categories:
Transfection 
Authors:
Yanfang Fu, Jeffry D. Sander, Deepak Reyon, Vincent M. Cascio, J. Keith Joung 
In:
Nat Biotechnol (2014) 32(3): 279-84 
Categories:
Transfection 
Authors:
M Kuhlwilm, A Davierwala, S Pääbo 
In:
PLoS ONE (2013) 8 (12): e83218 
Categories:
Transfection 
Authors:
Yanfang Fu, Jennifer A Foden, Cyd Khayter, Morgan L Maeder, Deepak Reyon, J Keith Joung, Jeffry D Sander 
In:
Nat Biotechnol (2013) 31(9): 822-6 
Categories:
Primary Cells and Media 
Authors:
Reikvam H, Nepstad I, Bruserud Ø, Hatfield KJ 
In:
OncoTarget (2013) 4(6): 830-43 
Categories:
Transfection 
Authors:
Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. 
In:
Nat Biotechnol (2012) 30(5): 460-465 
Categories:
Transfection 
Authors:
Schedlich LJ, Muthukaruppan A, O'han MK, Baxter RC 
In:
Mol Endocrinol (2007) 21(10): 2378-90 
Categories:
Transfection 
Authors:
McNeill DR, Wilson DM 3rd 
In:
Mol Cancer Res (2007) 5(1): 61 - 70 
Categories:
Transfection 
Authors:
Schmitt E, Boutros R, Froment C, Monsarrat B, Ducommun B, Dozier C 
In:
J Cell Sci (2006) 119(Pt 20): 4269-75 
Categories:
Transfection 
Authors:
Enari M, Ohmori K, Kitabayashi I, Taya Y 
In:
Genes Dev (2006) 20(9): 1087-99 
Categories:
Transfection 
Authors:
Gershan JA, Johnson BD, Weber J, Schauer DW, Natalia N, Behnke S, Burns K, Maloney KW, Warwick AB and Orentas RJ 
In:
Genet Vaccines Ther (2005) 3(1): 4 
+ Show All